Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by r ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

As Healio previously reported, oral semaglutide reduced risk for major adverse CV events (MACE) by 14% in high-risk adults with type 2 diabetes (HR = 0.86; 95% CI, 0.77-0.96; P = .0006 ...

The number of people poisoned by the incorrect use of weight loss medication is on the rise in the Netherlands. Last year, ...